Skip to main content
placeholder image

Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Journal Article


Abstract


UOW Authors


  •   De Souza, Paul (external author)

Publication Date


  • 2012

Citation


  • Ryan, C. J., Smith, M. R., De Bono, J. S., Molina, A., Logothetis, C., De Souza, P. L., . . . Rathkopf, D. E. (2012). Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 30(18_suppl), lba4518. doi:10.1200/jco.2012.30.18_suppl.lba4518

Web Of Science Accession Number


Start Page


  • lba4518

End Page


  • lba4518

Volume


  • 30

Issue


  • 18_suppl

Place Of Publication


Abstract


UOW Authors


  •   De Souza, Paul (external author)

Publication Date


  • 2012

Citation


  • Ryan, C. J., Smith, M. R., De Bono, J. S., Molina, A., Logothetis, C., De Souza, P. L., . . . Rathkopf, D. E. (2012). Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 30(18_suppl), lba4518. doi:10.1200/jco.2012.30.18_suppl.lba4518

Web Of Science Accession Number


Start Page


  • lba4518

End Page


  • lba4518

Volume


  • 30

Issue


  • 18_suppl

Place Of Publication